Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Verrica Pharmaceuticals reported significant growth in 2025, with total revenue increasing to $35.6 million from $7.6 million in 2024, marking a 368% increase [1][3] - The company achieved a 130% growth in net revenue for its product YCANTH, reaching $15.3 million in 2025, while reducing selling, general, and administrative expenses by over 40% [1][3] - The number of YCANTH dispensed applicator units grew by 99%, totaling 51,296 units in 2025 compared to 25,773 units in 2024 [1][3] Financial Performance - For the fourth quarter of 2025, product revenue was $3.7 million, up from $0.3 million in the same quarter of 2024 [14][17] - The company reported a net loss of $8.1 million for Q4 2025, a significant reduction from a net loss of $16.2 million in Q4 2024 [14][17] - For the full year 2025, the net loss was $17.9 million, compared to a net loss of $76.6 million in 2024, indicating improved financial health [17][19] Product Development and Regulatory Progress - The company is advancing its novel oncolytic peptide VP-315 towards a Phase 3 program for basal cell carcinoma, with supportive data indicating potential abscopal effects [1][5] - The first patient was dosed in a Phase 3 study for YCANTH targeting common warts in December 2025, with plans to initiate a second Phase 3 study in the US and Japan in mid-2026 [1][5] - Verrica gained alignment with the European Medicines Agency, allowing for a streamlined regulatory path for YCANTH's approval in the EU without additional clinical studies [1][4] Market Expansion and Partnerships - The company has launched its first international partnership for YCANTH with Torii Pharmaceutical in Japan, which has already received regulatory approval for the treatment of molluscum contagiosum [4][11] - The company is exploring additional commercialization partnerships to enhance funding and revenue opportunities, particularly following the positive feedback from European regulators [4][5] Operational Efficiency - The company has no outstanding debt and has extended its cash runway into the first quarter of 2027, indicating a strong liquidity position [1][3] - Selling, general, and administrative expenses for the full year 2025 were $35.2 million, down from $58.8 million in 2024, reflecting improved operational efficiency [17][19]